Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge

Vaccine

Volumn 24, Issue 31-32, 2006, Pages 5852-5861

  Liu, Wen Tssann ^a   Lin, Wei Ting ^a   Tsai, Chung Chin ^a   Chuang, Chuan Chang ^a   Liao, Chin Len ^a   Lin, Huang Chi ^a   Hung, Yao Wen ^a   Huang, Shih Shiung ^a   Liang, Chung Chih ^a   Hsu, Hui Ling ^a   Wang, Hsian Jenn ^a   Liu, Yu Tien ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Amphotericin B; Dengue virus; NS1; Prime boost regimen; Salmonella vaccine; Yersinia pestis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; HYBRID PROTEIN; IMMUNOGLOBULIN G; PROTEIN NS1; RECOMBINANT VACCINE; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; INFECTION PREVENTION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; YERSINIA PESTIS;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; DENGUE; DENGUE VIRUS; FEMALE; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; SALMONELLA VACCINES; VACCINES, SYNTHETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33745652909     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.066     Document Type: Article

References (60)

1. Westaway E.G., Brinton M.A., Gaidamorich S.Y., Horzinek M.C., Igarashi A., Kuariainen L., et al. Flaviviridae Intervirol 24 (1985) 183-192
2. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11 (1998) 480-496
3. Porterfield J.S. Antibody-dependent enhancement of viral infectivity. Adv Virus Res 31 (1986) 335-355
4. Rigau-Perez J.G., Clark G.G., Gubler D.J., Reiter P., Sanders E.J., and Vorndam A.V. Dengue and dengue haemorrhagic fever. Lancet 352 (1998) 971-977
5. Chambers T.J., Hahn C.S., Galler R., and Rice C.M. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44 (1990) 649-688
6. Henchal E.A., and Putnak J.R. The dengue viruses. Clin Microbiol Rev 3 (1990) 376-396
7. Kuhn R.J., Zhang W., and Rossmann M.G. Structure of dengue virus: implications for flavivrus organization, maturation, and fusion. Cell 108 (2002) 717-725
8. World Health Organization. Dengue haemorragic fever: Diagnosis, treatment, prevention and control. 2nd ed. (1997), WHO, Geneva
9. Rothman A.L. Dengue: defining protective versus pathologic immunity. J Clin Invest 113 (2004) 946-951
10. Kochel T., Wu S.J., Raviprakash K., Hobart P., Hoffman S., Porter K., et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicits neutralizing antibodies in mice. Vaccine 15 (1997) 547-552
11. Srivastava A.K., Putnak J.R., Warren R.L., and Hoke C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 13 (1995) 1251-1258
12. Feighny R., Burrous J., and Putnak R. Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge. Am J Tropic Med Hyg 50 (1994) 322-328
13. Parrish C.R., Woo W.S., and Wright P.J. Expression of the NS1 gene of dengue virus type 2 using vaccinia virus: dimerization of the NS1 glycoprotein. Arch Virology 117 (1991) 2279-2286
14. Bhamarapravati N., and Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 18 (2000) 44-47
15. Guirakhoo F., Pugachev K., Zhang Z., Meyers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78 (2004) 4761-4775
16. Innis B.L., and Eckels K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Material Command. Am J Trop Med Hyg 69 (2003) 1-4
17. Month T., and Heinz F. Flaviviruses. Fields virology. 3rd.ed. (1996), Lippincott-Raven Publishers, Philadelphia (PA) p. 961-1034
18. Schlesinger J., Foltzer M., and Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192 (1993) 132-141
19. Lai C.J., Zhang Y.M., Bray M., Chanock R., and Eckels K.H. Use of dengue virus structural proteins and non-structural protein NS1 produced by recombinant baculovirus for immunization against dengue virus infection. Vaccine 89 (1989) 351-356
20. Qu X., Chen W., Maguire T., and Austin F. Immunoreactivity and protective-effect in mice of a recombinant dengue 2 Tonga virus NS1 protein produced in a baculovirus expression system. J Gen Virol 74 (1993) 89-97
21. Schlesinger J.J., Brandris M.W., and Walsh E.E. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 68 (1987) 853-857
22. Puttikhunt C., Kasinerk W., Srisa-ad S., Duangchinda T., Silakate W., Moonsom S., et al. Production of anti-dengue NS1 monoclonal antibodies by DNA immunization. J Virol Methods 109 (2003) 55-61
23. Leblois H., and Young P.R. Sequence of the dengue virus type 2 (strain PR-159) NS1 gene and comparison with its vaccine derivative. Nucl Acids Res 21 (1993) 1668
24. Dougan G., Hormaeche C.E., and Maskell D.J. Live oral Salmonella vaccines: potential use of attenuated strains carriers of heterologous antigen to the immune system. Parasite Immunol 9 (1986) 151-160
25. Fagan P.K., Djordjevic S.P., Chin J.G., Eamens J.M., and Walker J. Oral immunization of mice with attenuated Salmonella typhimurium aroA expressing a recombinant Mycoplasma pneumonmiae. Infect Immun 65 (1997) 2502-2507
26. Hormaeche C.E., Khan C.M.A., Mastroeni P., Villarreal B., Dougan G., Roberts M., et al. Salmonella vaccines: mechanisms of immunity and their use as carriers of recombinant antigens. In: Ala' Aldeen D.A.A., and Hormaeche C.E. (Eds). Molecular and clinical aspects of bacterial vaccine development (1995), John Wiley & Sons Press 119-153
27. Russmann H., Shams H., Poblete F., Fu Y., Gal'an J.E., and Donis R.O. Delivery of epitopes by the Salmonella Type III secretion system for vaccine development. Science 281 (1998) 565-568
28. Kramer U., Rizos K., Apfel H., Autentrieth I.B., and Lattemann C.T. Autodisplay: development of an efficacious system for surface display of antigenic determinants in Salmonella vaccine. Infect Immun 71 (2003) 1944-1952
29. Mandell G.L., Bennett J., and Dolin R. Principles and practice of infectious diseases. 5th ed. Vol. 1 (2000) p. 448-59
30. Tritel M., Stoddard A.M., Flynn B.J., Darrah P.A., Wu C.Y., Wille U., et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligonucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171 (2003) 2538-2547
31. Karlyshev A.V., Galyov E.E., Smirnov O.Y., Guzayev A.P., Abramov V.M., and Zav'yalov V.P. A new gene of the F1 operon of Y. pestis involved in the capsule biogenesis. FEBS 297 (1992) 77-80
32. Karlyshev A.V., Galyov E.E., Smirnov O.Y., Abramov V.M., and Zav'yalov V.P. Structure and regulation of a gene cluster involved in capsule formation of Y. pestis. NATO ASI Series 82 (1994) 321-330
33. Oyston P.C., Williamson E.D., Leary S.E., Eley S.M., Griffin K.F., and Titball R.W. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plaque. Infect Immun 63 (1995) 563-568
34. Titball R.W., Howells A.M., Oyston P.C., and Williamson E.D. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plaque. Infect Immun 65 (1997) 1926-1930
35. Zavialov A.V., Batchikova N.V., Korpela T., Petrovskaya L.E., Korobko V.G., Kersley J., et al. Secretion of recombinant protein via the Chaperone/Usher pathway in Escherichia coli. Appl Environ Microbiol 67 (2001) 1805-1814
36. Hartsel S., and Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci 17 (1996) 445-449
37. Blanke T.J., Little J.R., Shirley S.F., and Lynch R.G. Augmentation of murine immune responses by amphotericin B. Cell Immunol 33 (1977) 180-190
38. Okutomi T., Ubukata T., Yamaoka K., Abe S., and Yamaguchi H. Augmentation of production of TNF-alpha and anti-tumour activity by an amphotericin B preparation for clinical use in mice. Br J Cancer 75 (1997) 1613-1616
39. Schindler J.J., Reed R.P., Allen S.D., and Jackson M.K. Immunological effects of amphotericin B on splenocytes from immune-normal and immune-compromised mice. Antimicrobial Antimicrob Agnets Chemother 37 (1993) 2716-2721
40. Hoiseth S.K., and Stocker B.A. Aromatic dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291 (1981) 238-239
41. Lin Y.L., Liao C.L., Chen L.K., Yeh C.T., Ma S.H., Huang Y.L., et al. Study of dengue virus infection in SCID mice engrafted within human K562 cells. J Virol 72 (1998) 9729-9737
42. Sambrook J., and Russell D.W. Molecular cloning: A laboratory manual. 3rd ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
43. Kado C.J., and Liu S.Y. Rapid procedure and isolation of plasmids. J Bacteriol 145 (1981) 1365-1373
44. Wu S.F., Liao C.L., Lin Y.L., Yeh C.T., Chen L.K., Huang Y.F., et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 21 (2003) 3919-3929
45. Misawa S., and Kumagai I. Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodys. Biopolymers 51 (1999) 297-307
46. Yeh M.K., Liu Y.T., Chen J.L., and Chiang C.H. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J Control Release 82 (2002) 237-247
47. Chapman D.A.G., Zavialova A.V., Chemovskaya T.V., Karlyshev A.V., Zav'yalova G.A., Vasillev A.M., et al. Structure and functional significance of the FGL sequence of the periplasmic chaperone, Caf1M, of Yersinia pestis. J Bacteriol 181 (1999) 2422-2429
48. Maclntyre S., Zyrianova I.M., Chernovskaya T.V., Leonard M., Rudenko E.G., Zav'yalov V.P., and Chapman D.A.G. An extended hydrophobic interactive surface of Yersinia pestis Caf1M chaperone is essential for subunit binding and F1 capsule assembly. Mol Microbiol 39 (2001) 12-25
49. Ho Y.K., Srinivasan J., and Cutrtiss III R. Immune responses to recombinant Pneumococcal PspA antigen delivered by live attenuated Salmonella enterica Serovar Typhimurium vaccine. Infect Immun 70 (2002) 1739-1749
50. Hahn H.P., and Specht B.-U. Secretory delivery of recombinant proteins in attenuated Salmonella strains: potential and limitations of Type I protein transporters. FEMS Immunol Med Microbiol 37 (2003) 87-98
51. Igwe E.I., Geginat G., and Russmann H. Concomitant cytosolic delivery of two immunodominant Listerial antigens by Salmonella enterica Serovar Typhimurium confers superior protection against murine Listeriosis. Infect Immun 70 (2002) 7114-7119
52. Garmory H.S., Titball R.W., Brown K.A., and Bennett A.M. Construction and evaluation of eukaryotic expression plasmid for stable Salmonella. Microb Pathog 34 (2003) 115-119
53. Garmory H.S., Griffin K.F., Jones S.M., Yates A., Harrington L., and Titball R.W. Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. Vaccine 18 (2000) 2668-2676
54. Kang H.Y., Srinivasan J., and Curtiss III R. Immune response to recombinant pneumoncoccal PspA antigen delivered by attenuated Salmonella enterica serovar Typhimurium vaccine. Infect Immun 70 (2002) 1739-1749
55. + T cell responses. Eur J Immunol 35 (2005) 2532-2540
56. Gosetsch L., Plotinicky-Gilquin H., Champion T., Beck A., Corvaia N., Stahl S., et al. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory synsytial virus subunit vaccine candidate. Vaccine 18 (2000) 2735-2742
57. Lin C.F., Lei H.Y., Shiau A.L., Liu H.S., Yeh T.M., Chen S.H., et al. Endothelial cell apotosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol 169 (2002) 657-664
58. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 4 1 (2002) 23-27
59. Mozaffarian N., Berman J.W., and Casadevall A. Enhancement of nitric oxide systhesis by macrophage represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother 41 (1997) 1825-1829
60. Sau K., Mambula S.S., Latz E., Henneke P., Golenbock T., and Levitz S.M. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 39 (2003) 37561-37568